Pfizer to acquire Medivation for $14 billion
Pharmaceutical giant Pfizer announced Monday that it has agreed to acquire Medivation in a $14 billion deal that would add a blockbuster drug to its cancer pipeline. Medivation, a San Francisco biopharmaceutical company, has been highly sought after in recent months. Its flagship product, Xtandi, is a prostate cancer treatment that generated $2.2 billion in sales over [...]